Research Article
No access
Published Online: 5 July 2004

Short Communication: Effect of Etanercept (Enbrel) on Interleukin 6, Tumor Necrosis Factor α, and Markers of Immune Activation in HIV-Infected Subjects Receiving Interleukin 2

Publication: AIDS Research and Human Retroviruses
Volume 18, Issue Number 9

Abstract

The effect of etanercept, a soluble p75 tumor necrosis factor (TNF) receptor:Fc fusion protein (Enbrel; Immunex, Seattle, WA) on plasma cytokines was evaluated in 11 HIV-infected subjects receiving highly active antiretroviral therapy (HAART) for 28 weeks with or without subcutaneous or intravenous recombinant human interleukin 2 (rhIL-2). Plasma IL-6 and C-reactive protein (CRP) levels increased after rhIL-2 treatment. Etanercept pretreatment attenuated these increases. Median plasma IL-6 levels were 20.29 pg/ml 4 days after rhIL-2 and 7.87 pg/ml 4 days after etanercept and rhIL-2 (p = 0.22); median CRP levels were 78.73 and 46.16 μg/ml, respectively (p = 0.03). An effect on TNF bioactivity could not be assessed as all measurements were below limits of detection. No significant changes were seen in temperature or plasma levels of IL-4, IL-10, IL-12, interferon γ, or HIV-1 RNA levels. All subjects had undetectable or low-level HIV-1 RNA levels before etanercept dosing. One subject died; however, her death was thought to be unrelated to etanercept. Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

cover image AIDS Research and Human Retroviruses
AIDS Research and Human Retroviruses
Volume 18Issue Number 9June 2002
Pages: 661 - 665
PubMed: 12079562

History

Published online: 5 July 2004
Published in print: June 2002

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Beverly E. Sha
Section of Infectious Diseases, Department of Medicine, and Department of Immunology/Microbiology, Rush Medical College, Chicago, Illinois 60612-3833
Hernan Valdez
Department of Medicine, Center for AIDS Research, Case Western Reserve University and University Hospitals, Cleveland, Ohio 44106-5000
Rebecca S. Gelman
Harvard School of Public Health, Boston, Massachusetts 02115-6013
Alan L. Landay
Section of Infectious Diseases, Department of Medicine, and Department of Immunology/Microbiology, Rush Medical College, Chicago, Illinois 60612-3833
Jan Agosti
Immunex Corporation, Seattle, Washington 98101
Ronald Mitsuyasu
University of California, Los Angeles, Los Angeles, California 90095-1793
Richard B. Pollard
University of Texas at Galveston, Galveston, Texas 77555-0435
Donna Mildvan
Division of Infectious Diseases, Department of Medicine, Beth Israel Medical Center, New York, New York 10003
Ann Namkung
Adult AIDS Clinical Trials Group Operations Center, Rockville, Maryland 20910
Debra M. Ogata-Arakaki
University of Hawaii at Manoa, Honolulu, Hawaii 96816-1032
Lawrence Fox
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-7620
Scharla Estep
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-7620
Alejo Erice
Infectious Disease Division, Department of Laboratory Medicine and Pathology and Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455-0392
Patrick Kilgo
Harvard School of Public Health, Boston, Massachusetts 02115-6013
Robert E. Walker
Aviron, Mountain View, California 94043
Lynne Bancroft
Frontier Science and Technology Research Foundation, Inc., Amherst, New York 14226-1056
Michael M. Lederman
Department of Medicine, Center for AIDS Research, Case Western Reserve University and University Hospitals, Cleveland, Ohio 44106-5000

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top